{'fraction_non_alphanumeric': 0.014492753623188406, 'fraction_numerical': 0.008918617614269788, 'mean_word_length': 5.27972027972028, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of the Economic Impact Produced by the Prevention of Events Induced by the HPV 6-11 Virus Types Contained in the Quadrivalent Vaccine

Although the integration of the fragmentary data concerning the total expenses borne for the early diagnosis and the treatment of HPV-induced pathologies is problematic, it is possible to break down the total burden of HPV-induced events into the leading determinants of cost. By entering the results obtained from several published studies into a model specifically designed to evaluate the economic effectiveness of the implementation of a multi-cohort vaccination strategy in Italy, it is possible to estimate the effect of the quadrivalent vaccine in terms of number of prevented events and the potential cost reduction. The quadrivalent vaccine should determine a significant cost-saving of 68.6%, corresponding to approximately 70 million euros.